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Abstract
Protein synthesis in mammalian mitochondria produces 13 proteins that are essential subunits of
the oxidative phosphorylation complexes. This review provides a detailed outline of each phase of
mitochondrial translation including initiation, elongation, termination, and ribosome recycling.
The roles of essential proteins involved in each phase are described. All of the products of
mitochondrial protein synthesis in mammals are inserted into the inner membrane. Several
proteins that may help bind ribosomes to the membrane during translation are described, although
much remains to be learned about this process. Mutations in mitochondrial or nuclear genes
encoding components of the translation system often lead to severe deficiencies in oxidative
phosphorylation, and a summary of these mutations is provided.
Keywords
Mammal; Mitochondria; protein synthesis; initiation; elongation; termination
1. Protein Biosynthesis in Mammalian Mitochondria
1.1 Role of Mitochondria in Energy Metabolism
Mitochondria produce over 90 % of the energy used by mammalian cells through oxidative
phosphorylation. They also carry out other critical functions including heme biosynthesis, a
portion of the urea cycle, and play a role in apoptosis. Mitochondria are generally viewed as
oblong-shaped organelles surrounded by two membranes. The outer membrane (OM)
outlines the overall shape and forms an envelope, which presents a barrier that restricts
passage to small molecules. The inner membrane (IM) is highly invaginated, forming
cristae, and surrounds the interior soluble portion, the matrix. The IM is actually composed
of two regions [1]. The inner membrane boundary (IMB) is closely associated with the OM
with which it has a number of contact sites. The cristal membranes (CM) make up the
majority of the surface of the IM. The IMB and the CM are connected by narrow, ring-like
structures that form a barrier between the intracristal space and the intermembrane space.
For simplicity, we will refer to the inner membrane (IM) throughout this manuscript as
including both the IMB and the CM. The IM is the site of oxidative phosphorylation which
generates most of the ATP used by aerobic cells.
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Mammalian mitochondria have their own genome, consisting of about 16,000 base pairs of
DNA encoding 2 rRNAs, 22 tRNAs and 13 polypeptides organized very compactly. The
genes are generally directly adjacent to each other or are separated by only a few
nucleotides. There is nearly a complete absence of non-coding regions. The genetic code has
been slightly modified in animal mitochondria compared to the universal code [2]. For
example UGA that normally serves as a stop codon is read as tryptophan in animal
mitochondria. In addition to AUG, the AUA codon for isoleucine is read as methionine.
While the AGA and AGG codons for arginine have been thought to act as stop codons,
recent evidence suggests that they are used in −1 frameshifting (see Section 4.1) [3].
All of the proteins synthesized by the mitochondrial translational system are localized in the
IM where they function as subunits in the electron transfer and ATP synthase complexes [4].
These include seven subunits of Complex I (NADH:ubiquinone oxidoreductase), one
subunit from complex III (ubiquinone:cytochrome c oxidoreductase), three subunits from
complex IV (cytochrome c:oxygen oxidoreductase) and 2 subunits of complex V (ATP
synthase). The remaining 2,000 or so proteins present in mammalian mitochondria are the
products of nuclear genes; they are synthesized in the cell cytosol and subsequently
imported into the organelle. The synthesis of the oligomeric respiratory chain complexes
requires the coordinate expression of genes in both the nuclear and mitochondrial genomes.
How this process is regulated in not currently known.
1.2 General Features of Mammalian Mitochondrial Protein Synthesis
Despite many years of research, no in vitro translation system capable of correct initiation
and synthesis of a mitochondrially encoded protein has been established from mammalian
mitochondria, and much remains to be learned about this process. However, a number of the
individual steps of mammalian mitochondrial protein synthesis have been successfully
carried out in vitro providing information on specific features of this system. This review
will focus on studies of the auxiliary factors required for mammalian mitochondrial protein
synthesis. Brief mention will be made of major differences observed with the translational
systems in lower eukaryotes.
Mammalian mitochondria contain a distinct set of ribosomes which, in mammals, sediment
as 55S particles and consist of 28S small subunits and 39S large subunits [5]. These
ribosomes have a molecular mass of about 2.7 × 106 daltons, roughly the size and shape of
the Escherichia coli ribosome. Animal mitochondrial ribosomes have only two rRNA
species, 12S in the small subunit and 16S in the large subunit, and are only 25 to 30% RNA
[6]. A recent report, however, suggests that these ribosomes may also carry a 5S rRNA [7].
In contrast, bacterial ribosomes contain 60-70% RNA and eukaryotic cytoplasmic ribosomes
are 50-60% RNA [7,9]. Comparisons of the primary sequences of the mitochondrial rRNAs
with those of prokaryotes and eukaryotes show that there is only a small amount of identity
between these rRNAs. The smaller mitochondrial rRNAs are not shortened at random
positions throughout the primary sequence [10,11]. Rather, they lack either certain regions
of secondary structure or entire domains [12].
Most of the mitochondrial ribosomal proteins have been identified using proteomics [13-18].
The small subunit of the bovine mitochondrial ribosome has about 29 proteins, of which 14
have homologs in prokaryotic ribosomes, while 15 are specific for mitochondrial ribosomes.
Only six of these mitochondrial specific proteins have homologs in yeast mitochondrial
ribosomes [19]. The large subunit has about 48 proteins. Of these, 28 are homologs of
bacterial ribosomal proteins while the remaining 20 are unique to mitochondrial ribosomes.
Again, only nine of these mitochondrial specific ribosomal proteins have homologs in yeast,
indicating significant divergence between the protein composition of the mitochondrial
ribosomes between the higher and lower eukaryotes. Many of the proteins with homologs in
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bacterial systems are significantly larger than their counterparts. Database analysis suggests
that the human mitochondrial ribosome has a comparable spectrum of proteins as observed
in the bovine system. For detailed information on mammalian mitochondrial ribosomes, the
reader is referred to two recent reviews [12,20].
The 13 proteins coded for in the mitochondrial genome are translated from 9 monocistronic
and 2 dicistronic mRNAs. Both dicistronic mRNAs contain overlapping reading frames
[21,22]. With the exception of the two internal start sites found in the dicistronic mRNAs,
the remaining 11 start sites are located at or near the 5′ end of each mRNA [23]. Thus,
mitochondrial mRNAs lack the canonical Shine-Dalgarno sequence used in prokaryotes to
help position the start codon at the P-site of the ribosome. Direct analysis of the 5′ ends of
the eleven open reading frames located at the 5′ ends of the human mitochondrial mRNAs
indicates that post-transcriptional processing completely eliminates the 5′ leader in all but
three mRNAs [23] which have 1, 2 and 3 nucleotides 5′ to the start codon. None of the 5′
cistrons of Drosophila melanogaster mitochondrial mRNAs begin with noncoding
nucleotides [24]. The start codon at the 5′ end can be either AUG or AUA, both of which
encode methionine in mammalian mitochondria. These codons direct the insertion of
formylmethionine during initiation and methionine during chain elongation. In bovine
mitochondria, AUG serves as the start codon for 10 genes while AUA is used for the
remaining three genes. AUA is the dominant codon for methionine during chain elongation.
The secondary structures at the 5′ ends of all the protein coding regions in the bovine
mitochondrial transcriptome were analyzed at single nucleotide resolution using RNA
SHAPE chemistry [25]. This analysis indicated that the 5′ ends of the mitochondrial
mRNAs are quite unstructured [26] as indicated in the examples in Fig 1. The start codon
tends to lie in a single-stranded region or in a very weak duplex stem.
Animal mitochondria have 22 tRNAs, one for each amino acid except for leucine and serine
that have two each. The tRNAs found in mammalian mitochondria have a number of
unusual features distinguishing them from canonical tRNAs. They are generally shorter that
other tRNAs and often lack the conserved or semi-conserved nucleotides that play important
roles in creating the L-shaped tertiary structure of prokaryotic and eukaryotic cytoplasmic
tRNAs. Chemical and enzymatic probing has led to the idea that these tRNAs fold into the
basic cloverleaf structure of canonical tRNAs, but lack a number of conserved tertiary
interactions and have a weaker three-dimensional structure [27-31]. In particular, a number
of the long-range interactions between the D-and T-arms of the tRNAs appear to be missing
[32,28,27,33]. No direct structural information is available on a mitochondrial tRNA;
however, cryo-EM of the mitochondrial ribosome shows a tRNA tightly bound at the P-site
that is basically an L-shape with a caved-in elbow region [34]. The structure of this tRNA
can be fitted into the crystallographic coordinates of canonical tRNAs except in the region
of the elbow where the smaller sizes of the T- and D-loops of many mitochondrial tRNAs do
not fit well into the structure of bacterial tRNAs.
The process of protein biosynthesis takes place in four phases, each requiring a set of
auxiliary factors. During initiation, the start site on the mRNA is selected and the initiator
tRNA (fMet-tRNA) is base-paired to the mRNA in the P-site of the ribosome. During
elongation the codons in the mRNA are read sequentially while the amino acids are
incorporated into the growing polypeptide chain. At termination and ribosome recycling, the
completed polypeptide is released and ribosome complex is dissociated.
1.3 Experimental Approaches to studying mitochondrial translation
Despite a number of years of effort, no in vitro system has been established that will carry
out the complete translation of a mammalian mitochondrial mRNA. Hence, most of what we
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currently understand about this process is based on partial reactions carried out using
purified components. Initiation complex formation and the activities of the individual
initiation factors are measured by the binding of [35S]fMet-tRNA to mitochondrial
ribosomes or the small ribosomal subunit in the presence of poly(A,U,G) or an in vitro
transcript of a mitochondrial mRNA [35,36]. Chain elongation is studied using purified
mitochondrial ribosomes and elongation factors. The partial reactions of chain elongation
are assayed by measuring the binding of [14C]Phe-tRNA to ribosomes in the presence of a
poly(U) mRNA and the full elongation cycle is monitored by the polymerization of
[14C]Phe into poly(Phe) as described in detail [37].
2. Initiation of Protein Synthesis in Mammalian Mitochondria
2.1 Model for Translational Initiation in Mammalian Mitochondria
Two mitochondrial initiation factors have been identified, mitochondrial initiation factor 2
(IF2mt) and mitochondrial initiation factor 3 (IF3mt). Using these two factors alone, it is
possible in vitro to assemble an initiation complex on 55S ribosomes with fMet-tRNA
correctly positioned at the start codon of a mitochondrial mRNA [36]. However, the process
in vivo could be more complex and subject to significant regulation.
In the current working model for the initiation of translation in this minimal mitochondrial
system (Fig. 2), the first step in initiation is the active dissociation of the 55S ribosome by
IF3mt. In this step IF3mt interacts with the 55S particle loosening the interaction of the two
subunits (Step 1), leading to the release of the 39S subunit and the formation of a 28S:IF3mt
complex (Step 2). The timing of the binding of IF2mt:GTP is not clear at the present time
and is show in Step 3 for convenience only. The mRNA feeds into the 28S subunit via a
protein-rich mRNA entrance gate observed in the small subunit [34] (Step 4). The binding of
the mRNA is thought to precede fMet-tRNA binding, because IF3mt has been shown to
destabilize the fMet-tRNA bound to 28S subunits in the absence of mRNA (see Section
2.4.4). Toeprinting analysis [36] has indicated that when the first 17 nucleotides of the
mRNA have entered the ribosome, the movement of the mRNA is paused while the 28S
subunit inspects the codon at the 5′ end of the mRNA (inspection option in Step 4). During
this pause, IF2mt:GTP can promote the binding of fMet-tRNA to the ribosome. If there is a
start codon exposed in the P-site, codon:anticodon interactions between the fMet-tRNA and
the 5′ AUG start codon lead to a stable initiation complex. If no codon:anticodon
interactions can form due to a lack of fMet-tRNA and/or to the absence of a 5′ start codon,
the mRNA resumes sliding through the small subunit and eventually dissociates. Following
fMet-tRNA binding to the 5′ start codon, the large subunit joins the 28S initiation complex,
IF2mt hydrolyzes GTP to GDP, and the initiation factors are released, resulting in a
completed 55S initiation complex that is ready to enter elongation phase of protein synthesis
(Step 5).
Consideration of the mechanism of polypeptide chain initiation in mammalian mitochondria
must take into account the unusual properties of the mRNAs present, particularly the
location of the start codon at or very near the 5′ end of the mRNA. To illustrate the
importance of the leaderless nature of mitochondrial mRNAs, a series of 5′ extended
mRNAs was prepared using the mRNA for subunit II of cytochrome oxidase containing 1,
2, 3, 6, 9 or 12 nucleotides prior to the 5′ start codon [36]. The formation of the initiation
complex was slightly reduced by the addition of a single nucleotide prior to the 5′ AUG and
the presence of only 3 nucleotides preceding the AUG codon led to more than a 40 %
reduction in initiation complex formation. Additional nucleotides prior to the AUG start
codon led to yet further decreases in initiation complex formation, with an 80% reduction in
initiation complex formation observed when 12 nucleotides were present 5′ to the start
codon. This result indicates that the ribosome is very inefficient in recognizing the start
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codon of mRNAs with more than 3 nucleotides 5′ to the AUG and suggests that post-
transcriptional processing of the long primary transcript of the mitochondrial DNA is likely
to occur prior to translation.
2.2. Mitochondrial Translational Initiation Factors 1 and 2
2.2.1 Background—As indicated in Section 2.1, the general mitochondrial translation
machinery involves two initiation factors, IF2mt and IF3mt. Although IF1 has been viewed
as a universal translational initiation factor, no corresponding factor has been identified in
any mitochondrial system to date.
2.2.2. The IF2mt Gene—The gene for IF2mt (MIF2) is located on chromosome 2 and
spans 33.5 kilobases [38]. It has 16 exons and 15 introns. Several single nucleotide
polymorphisms are observed in this gene. The transcriptional start site is located 296 base
pairs upstream of the AUG start codon. Three upstream AUG codons are present in the 5′
untranslated region of the IF2mt mRNA. Two of these are in-frame while the third is in a
different reading frame. These extra AUG codons are likely to down-regulate the synthesis
of IF2mt, which is estimated to be present in only 10-20 copies per mitochondrion.
Transcription of the MIF2 gene generally correlates with the energy demands of the tissue
[39]. No direct studies have been carried out on the regulation of expression of the IF2mt
gene. However, the transcription start site contains binding sites for transcription factors
Sp1, nuclear respiratory factor 2 (NRF-2) and the estrogen receptor [38] suggesting a
complex pattern of regulation.
Native IF2mt was purified a number of years ago [40,41]. The purified factor is capable of
promoting the binding of the initiator tRNA (fMet-tRNA) to mitochondrial 28S subunits or
55S ribosomes in the presence of a mRNA such as the AUG triplet or poly(A,U,G). This
binding is stimulated significantly by GTP. Bovine IF2mt can stimulate the binding of fMet-
tRNA to bacterial ribosomes in addition to mitochondrial ribosomes. However, the converse
is not true, and E. coli IF2 is not active on mitochondrial ribosomes [41].
2.2.3. Characteristics of the IF2mt Coding Sequence—Several different
nomenclatures have been used to describe the domain architecture of the IF2 from various
organisms. For convenience we have used the nomenclature that divides E. coli IF2 into six
domains (Fig. 3). Doman I in E. coli IF2 is present in the longest version of this factor
(IF2α) but is absent in a shorter in vivo form (IF2β). The role of this domain is not known
and it is absent in the IF2 species from many organisms. Domain II is thought to play a role
in the interaction of IF2 with the small ribosomal subunit [42]. Domain III is poorly
characterized but may also make contact with the small ribosomal subunit. The guanine
nucleotide binding domain (G-domain, domain IV) is the most highly conserved region of
the IF2 species from various organisms and carries the signature sequences for typical G-
proteins. Domain V is also thought to play a role in ribosome binding. Finally domain VI is
divided into 2 subdomains (C1 and C2). The C2 subdomain is directly involved in the
interaction of IF2 with fMet-tRNA [43,44].
IF2mt begins with a mitochondrial import signal. Two natural variants of the IF2mt coding
sequence have been noted and the first of these is found in the import sequence. The N-
terminus of the mature protein is blocked and the actual start position of the mature form of
this factor is unknown [45]. Initial predictions suggested that the import signal would
encompass the first 28-29 amino acids and this is the current prediction using TargetP [46].
However, MitoProtII [47] predicts a 77 amino acid import signal and PSort2 predicts an 86
residue import signal [48]. Most of the work on the properties of IF2mt expressed in E. coli
has been carried out on the version of the protein encompassing residues 78-727. This form
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is stably expressed in bacterial cells. Constructs based on a shorter import signal give rise to
extensive proteolysis products and aberrant internal initiation products when expressed in E.
coli [49]. The second variant of the IF2mt coding sequence is a conservative change of Val
to Ile at amino acid 556.
Considering a mature form of IF2mt beginning at amino acid 78, the mitochondrial factor
encompasses domains III-VI viewed on the basis of the six-domain model of E. coli IF2
(Fig. 3). Of these domains, the G-domain is the most highly conserved. For a detailed
analysis of the conservation of these domains, the reader is referred to a previous review
[50]. Of particular interest is the presence of a small insert of 37 amino acids present in the
mitochondrial factor but not observed in the prokaryotic factors (discussed in 2.2.6) [51].
This insertion is located between domains V and VIC1 and its role is discussed below. It
should be noted that there is no closer relationship between mammalian IF2mt and yeast
IF2mt than between the mammalian factor and the IF2 of bacteria. This observation reflects
the substantial divergence of the mitochondrial translational systems of the higher and lower
eukaryotes.
2.3.4. Interaction of IF2mt with (f)Met-tRNA—Mammalian mitochondria are unique in
having a single species of tRNAMet. Other translational systems, including the
mitochondrial systems of plants and the lower eukaryotes, have separate tRNAMet species
for initiation and elongation. Mitochondrial tRNAMet is aminoacylated with methionine and
the Met-tRNA interacts with elongation factor Tu (EF-Tumt) for use in translational
elongation. A portion of the Met-tRNA is formylated to serve in initiation. Mammalian
mitochondria must, therefore, have a method to partition the single Met-tRNA into the
initiation and elongation processes. Bovine mitochondrial Met-tRNA transformylase has
been cloned and the protein has been studied biochemically [52,53]. The partitioning of
Met-tRNA between initiation and elongation is postulated to arise through competition
between the transformylase and EF-Tumt. If the Met-tRNA is formylated, it interacts with
IF2mt and participates in chain initiation [54]. IF2mt shows a nearly 50-fold preference for
the formylated initiator tRNA. If the Met-tRNA interacts with EF-Tumt•GTP, it is channeled
to chain elongation. EF-Tumt does not interact with fMet-tRNA to a detectable extent. The
region of IF2mt responsible for interacting with the fMet-tRNA has been mapped to the
VIC2 subdomain [54].
In yeast mitochondria, formylation of Met-tRNA is not absolutely required for chain
initiation, and yeast mutants that cannot formylate the initiator tRNA can carry out
mitochondrial protein synthesis [55,56]. The ability of the yeast mitochondrial translational
system to function without formylation of Met-tRNA is dependent on the presence of a
factor designated Aep3p that is thought to interact with yeast IF2mt and facilitates its use of
Met-tRNA [57]. There is no clear homolog of this protein in mammals although it has a
weak homology to the small subunit ribosomal protein MRPS27 (e = 9.3×10−2).
2.2.5. Binding of IF2mt to the Small Subunit—The effects of various ligands on the
binding of IF2mt to mitochondrial 28S subunits were examined using pull-down assays with
biotinylated ribosomal subunits and streptavidin beads [51]. The mature form of IF2mt binds
to the small subunit with a Kd of about 10-20 nM. This binding is strongly influenced by the
presence of the non-hydrolyzable GTP analog GDPNP. Binding was reduced about 3-fold
when GDP was used in place of GDPNP and over 10-fold when guanine nucleotides were
omitted from the reaction mixture. For the full-length factor, the addition of fMet-tRNA and
mRNA did not affect the binding of IF2mt to the 28S subunit.
The roles of the individual domains of IF2mt on the binding of this factor to mitochondrial
28S subunits were examined using a series of deletion derivatives [51]. Domain III plays an
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important role in the interaction of this factor with the ribosome and makes important
contacts with the 28S subunit. Removal of domain IV, the G-domain, inactivates IF2mt as
expected and also prevents effective binding to 28S subunits. Domain IV is not expected to
interact with the small subunit since the G-domain should interact with the 39S subunit in
the vicinity of the ribosomal L7/L12 stalk and the sarcin-ricin loop similar to the other
translational G-proteins [58,59]. Presumably the presence of the G-domain is necessary for
the correct arrangement of the domains to allow ribosome binding. Domain VI and in
particular domain VIC2 is involved with the binding of the initiator tRNA. To achieve
further insight into the function of the 37 amino acid insertion in IF2mt (Section 2.2.3),
several residues in this amino acid stretch were mutated [51]. These mutations caused a
significant reduction in the ability of IF2mt to bind to the 28S subunit indicating that this
region plays an important role in the interaction of this factor with the small subunit.
2.2.6. Role of the Insertion Domain in IF2mt—IF1 is a small protein (71 amino acids
in E. coli) that has been viewed as a “universal” initiation factor being present in both
prokaryotic and eukaryotic cytoplasmic systems. No mitochondrial translational system has
been shown to possess a factor equivalent to IF1. Studies with bovine IF2mt indicated that
this factor is active on E. coli ribosomes but that its activity is not stimulated significantly by
IF1 [60] suggesting that the mitochondrial factor might possess a region functionally
equivalent to IF1. The best candidate for such a region is the 37 amino acid insertion present
between domains V and VI of the mitochondrial factor (Fig. 3). To test this possibility, a
strain of E. coli was constructed carrying a deletion of the infB gene encoding IF2 (ΔIF2).
This deletion is lethal unless complemented by a source of functional IF2. Interestingly, an
expression construct of IF2mt supported growth of the E. coli ΔIF2 strain, indicating that the
mitochondrial factor is functional in this prokaryotic system. The infA gene encodes IF1 and
its deletion is also lethal to E. coli. Interestingly, IF2mt was able to support the growth not
only of the ΔIF2 strain but was also able to rescue cells carrying deletions in both the IF2
and the IF1 genes. This observation indicates that IF2mt plays the role of two initiation
factors in mitochondria. When the 37 amino acid insertion in IF2mt was deleted, the
truncated factor could still support the growth of the ΔIF2 strain but could not support
growth of the ΔIF2ΔIF1 strain. Thus, it appears that the insertion in the mitochondrial
protein serves the function of IF1 for mitochondria. Biochemical assays confirmed this
conclusion [60].
E. coli IF1 binds to the bacterial 30S subunit near the aminoacyl-tRNA binding site, the A-
site, blocking this site during polypeptide chain initiation [61,62]. To assess whether the 37
amino acid insertion in IF2mt interacts with the same binding site on the ribosome, cryo-
electron microscopy was performed on an E. coli initiation complex formed with 70S
ribosomes, IF2mt, fMet-tRNA, mRNA and GDPNP [63]. IF2mt makes extensive contacts
with the interface sides of both ribosomal subunits extending from the lower body of the
ribosome to the decoding center (Fig. 4A). Analysis of this complex indicates that domains
III, V and VIC1 interact with the 30S subunit; the G-domain (IV), portions of domain VIC1
and parts of domain VIC2 contact the large subunit. Domain VIC2 also interacts with the -
CCA end of the fMet-tRNA.
The insertion domain of IF2mt occupies the same general position in the initiation complex
as does E. coli IF1. It makes contact with portions of helices 18 and 44 as well as ribosomal
protein S12. Although the insertion is only about half the size of IF1, its position in the 70S
initiation complex clearly overlaps the position occupied by IF1. This data and the ability of
IF2mt to replace both IF1 and IF2 in vivo argue strongly that a single initiation factor in
mammalian mitochondria serves the role of two bacterial initiation factors. The interior of
the mitochondrion is very densely packed and is thought to have a protein concentration of
800 mg/mL compared to about 300 mg/mL in bacterial cells [64]. Further, the invaginations
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in the inner membrane limit diffusion. The integration of the function of IF1 into IF2mt may
have occurred during evolution to circumvent problems arising from the crowded and
topologically complex structure of this organelle.
Examination of the electron density of the 70S initiation complex formed with IF2mt
allowed the development of a three-dimensional model for the structure of this factor (Fig.
4B). This model does not include domain III. Although electron density for this region of
IF2mt could be observed, no structural information on homologous proteins is known for this
domain preventing the development of an accurate model for this region of the factor. The
model for the remainder of IF2mt was based on the crystal structure of Methanobacterium
thermoautotrophicum aIF2 and the NMR structures of the VIC1 and VIC2 domains of
Bacillus (now Geobacillus) sterarothermophilus [63]. In this model, IF2mt resembles the
structure of the archaeal and eubacterial factors with the exception of the 37 amino acid
insertion. The insertion projects from the body of the protein between domains V and VIC1.
2.3. Mitochondrial Translational Initiation Factor 3
2.3.1 Background—Cybersearching of the human EST database with the sequences of a
number of bacterial IF3 species did not reveal the presence of IF3mt. However, searches
using the sequence of Mycoplasma IF3 or Euglena gracilis chloroplast IF3 as queries
provided hits in the human and mouse ESTs [65].
2.3.2. Characteristics of the IF3mt Coding Sequence—The coding region of IF3mt
encompasses 278 amino acids. Native mammalian mitochondrial initiation factor 3 (IF3mt)
has never been purified and the actual N-terminus is not known. MitoProtII, PSort2 and
TargetP all predict that this protein will be localized to mitochondria but all predict a
different import signal cleavage site. For expression studies we have used the prediction by
MitoProtII which suggests that human IF3mt will have a 31 amino acid import signal giving
rise to a 247 amino acid mature form of the protein.
The organization of IF3mt based on a 31 amino acid import signal shows a central region
with homology to the bacterial factors (Fig. 5) [65]. The prokaryotic factors are organized
into an N-terminal domain and a C-terminal domain separated by a flexible linker of about
27 amino acids. Removal of the import signal of IF3mt leaves a 29 kDa protein that has
regions with homology to the N- and C-terminal domains of bacterial IF3. The N-terminal
homology domain is preceded by an extension of 31 amino acids and there is an extension
of 33 amino acids following the C-terminal domain. Quite short N-terminal extensions
compared to E. coli and related IF3 species are observed in a few prokaryotes. A long N-
terminal extension is observed in Euglena gracilis chloroplast IF3 (about 150 amino acids).
Clear homologs of human IF3mt are observed in the genomes of other mammals where the
sequences are generally more than 60 % conserved. Lower conservation (about 35-40 %) is
observed with the IF3mt of other vertebrates. It is more of a challenge to identify a putative
IF3mt in the genomes of invertebrates. Reasonable candidates are observed in the
Arthropoda including Drosophila and several mosquito genera. No convincing homolog is
observed in Ceanorhabditis elegans although other nematodes such as Trichinella spiralis
have reasonable candidates for IF3mt. Homologs of IF3mt can be observed in several fungi
although no biochemical characterization of these proteins has been carried out to
demonstrate their possible role in mitochondrial protein synthesis. Interestingly, no clear
homolog of IF3mt is observed in the genome of Saccharomyces cerevisiae.
The homology domains of IF3mt are not particularly well conserved compared to bacterial
IF3. In general, there is less than 25 % identity between the mammalian mitochondrial and
bacterial factors. Overall, the C-terminal domain is more highly conserved than the N-
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terminal domain. The greatest homology to prokaryotic factors is observed with the IF3
from Elusimicrobium minutum and Dictyoglomus turgidum as well as several species of
Mycoplasma. The evolutionary implications of the homology of IF3mt to various bacterial
factors are not clear.
Although there is a low percent homology between G. stearothermophilus IF3 and the
mammalian mitochondrial factor (23 %), the structure of the N-terminal homology domain
of IF3mt can be modeled using Insight II based on the X-ray structure of G.
stearothermophilus (formerly Bacillus) IF3 [66]. This region of IF3 is folded into a helical
unit that is packed against a four stranded β-sheet (Fig. 5B). A second helical segment
projects into the linker region. The N-terminal extension cannot be modeled and is predicted
to be unstructured in solution. Presumably it assumes structure upon binding to the small
ribosomal subunit.
The C-terminal domain of IF3mt has been modeled based on the NMR structure of the C-
terminal domain of mouse IF3mt (PDB coordinates 2CRQ). This domain consists of two α-
helices that lie on top of a 4-stranded β-sheet. The C-domain of the human IF3mt is 72 %
identical to that of the mouse factor and this domain of human IF3mt is predicted to fold into
a similar structure except that one of the β-strands breaks into two sections due to the
presence of an internal proline residue. The NMR structure of the mouse factor does not
include the C-terminal extension and no structure for this region could be predicted using
Insight II.
The crystal structure of G. stearothermophilus IF3 indicates that the linker is α-helical and
the model using this structure predicts a partially α-helical linker region. However,
biochemical studies of IF3 indicate that the linker region has considerable flexibility and
may assume a fixed structure only when IF3 binds the ribosome [67-69].
2.3.3. The IF3mt Gene—The gene for IF3mt covers nearly 15 kilobase pairs and is located
on chromosome 13 (q12.2). A pseudogene is located on chromosome 5. A number of splice
variants are observed. Four major mRNAs differing in the 5′ untranslated region (UTR) are
listed in RefSeq at NCBI. These do not correspond exactly to the analysis of the gene in
Emsembl but are close. The mRNAs range from 999 to 1098 nucleotides in length. They
direct the synthesis of the same protein that is encoded by the last three exons of the gene.
The differences in the 5′ UTR arise from the selection of different start sites and alternate
splicing. Analysis of the 5′ UTRs indicate that all of the four major mRNAs have upstream
open reading frames (uORFs) that could influence the level of expression of the IF3mt
protein. In general, the uORFs are not present in a particularly good Kozak context [70] but
could initiate to some extent. In all four variants, one would expect these uORFs to reduce
the amount IF3mt synthesized. This observation is compatible with the idea that the amount
of IF3mt is quite low, on the order of 10-20 molecules per mitochondrion.
Two natural polymorphisms are observed in human IF3mt. The first is a Thr to Leu variant
located in the beginning of the N-terminal homology domain at position 68. A second
variant is found at the beginning of the C-terminal extension (position 247) with a Phe to
Leu change. It is unlikely that either of these changes would affect the properties of IF3mt.
However, a silent mutation at nucleotide 798 of the coding region is correlated with
Parkinson’s disease [71]. This mutation is believed to reduce the stability of the IF3mt
mRNA leading to a reduction in the amount of this factor in mitochondria and, hence, to a
reduction of mitochondrial protein synthesis. Defects in the assembly of the respiratory
chain complexes could lead to oxidative stress to which dopaminergic neurons may be
particularly sensitive.
Christian and Spremulli Page 9













2.4.4. Biological Roles of IF3mt and Analysis of Critical Regions of this Factor
—IF3mt promotes the binding of fMet-tRNA to the mitochondrial 55S ribosome in the
presence of IF2mt and mRNA. This stimulation is largely due to the ability of this factor to
promote the dissociation of the ribosome into the large and small subunits allowing mRNA
and initiator tRNA binding to the 28S subunit [65]. IF3mt has another interesting activity not
observed in prokaryotic systems and that is the ability to dissociate fMet-tRNA bound to
ribosomes in the absence of mRNA. This observation suggests that there may be a required
order of assembly of the initiation complex with mRNA binding preceding the binding of
the fMet-tRNA [72] (See model in Fig. 2). In eubacteria, IF3 is thought to proofread the
initiation complex and to promote the dissociation of aminoacyl-tRNAs bound at non-AUG
codons. However, the residues thought to be important for this activity in bacterial IF3 are
not conserved in the mitochondrial factor [69,73,74] and no proofreading ability has been
observed with this factor. It should be noted that mitochondrial ribosomes initiate translation
with both AUG and AUA and that the lone tRNAMet species participates both in chain
initiation and in chain elongation perhaps making a traditional proofreading activity for
IF3mt unlikely.
The binding of IF3mt to mitochondrial 28S subunits has been studied by a number of
methods including surface plasmon resonance, micron centrifugation and sucrose density
gradient centrifugation [75]. The full-length mature form of this factor binds to the small
subunit with a Kd of about 30 nM. The C-domain with the linker also binds tightly with a Kd
of about 60 nM. When the linker region is removed, the binding affinity decreases to a Kd of
about 95 nM. These observations indicate that there are strong contacts between the C-
terminal domain and the 28S subunit and that the linker slightly enhances these interactions.
The C-terminal domain is believed to bind to the platform region of the small subunit
(section 2.3.5) where it would block several intersubunit bridges that form in the intact
monosome. The strong affinity of the C-terminal domain for the small subunit is in contrast
to observations made in the E. coli system in which the C-domain alone has a 100-fold
lower affinity for the 30S subunit than the intact factor [73]. The C-domain of IF3mt alone is
as active as the full-length mature form of the factor when tested for the ability to promote
initiation complex formation with mitochondrial 55S ribosomes. This observation reflects
the idea that this assay measures primarily the ability of IF3mt to promote ribosome
dissociation. In independent tests, the C-domain has been shown to be about 9-fold less
effective than the full-length factor in promoting the dissociation of 55S ribosomes. This
decrease in ribosome dissociation is apparently not limiting for the initiation complex assay.
Mutagenesis has been used in an effort to define the regions of IF3mt that are important for
its activity [66]. Mutations of residues 170-171 and of residue 175 to alanine in the C-
terminal domain of IF3mt lead to an almost complete loss of activity in promoting initiation
complex formation and in the dissociation of 55S ribosomes into subunits. Surprisingly,
both of the inactive derivatives of IF3mt can bind to 28S subunits as well as the wild-type
factor indicating that a defect is small subunit binding is not responsible for the loss of
activity in promoting initiation complex formation. Rather, it appears that the mutations lead
to a factor that is unable to promote the dissociation of 55S ribosomes into free 39S subunits
and the 28S:IF3mt complex. This observation strongly suggests that IF3mt acts as an active
ribosome dissociation factor and not as a passive anti-association factor (Fig. 2).
The N-terminal domain of IF3mt also binds rather well to the 28S subunit (Kd about 240
nM) in the absence of other factors [75]. This observation is in sharp contrast to those made
in bacterial systems in which no binding of the N-terminal domain alone can be observed to
the small subunit. The linker provides some of this interaction energy for the binding of the
N-terminal domain of IF3mt to the small subunit and, when it is removed, the Kd is
noticeably weaker (390 nM). The isolated N-terminal domain is not detectably active in
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promoting the dissociation of the 55S monosome and has little activity in promoting
initiation complex formation. These results provide a picture of IF3mt as a dumbbell shaped
molecule in which there are extensive contacts between both the N- and C-terminal domains
and the small subunit. The linker optimizes the affinity of these domains for the 28S subunit
making it more difficult for the large subunit to displace the factors from the 28S subunit.
The dissociation of the 55S ribosome by IF3mt requires the binding of this factor to the small
subunit, thereby excluding its interaction with the 39S subunit. Full-length IF3mt has
essentially no affinity for the large subunit (Kd = 1.5 μM, about 50-fold weaker than binding
to the 28S subunit). However, deletion of the extensions results in about a 10-fold increase
in the affinity of IF3mt for the large subunit. The N-terminal extension accounts for most of
this effect with a small contribution from the C-terminal extension. This observation
suggests that the N-terminal extension on IF3mt could have evolved to reduce the affinity of
the factor for the large subunit, thereby promoting the proper interaction of the factor with
the 28S subunit during initiation.
As indicated in the current working model for initiation in mammalian mitochondria (Fig.
2), mRNA binding is thought to precede the binding of fMet-tRNA. One of the roles of
IF3mt is to promote the dissociation of any fMet-tRNA that binds to the 28S subunit prior to
the mRNA. When the C-terminal extension is removed, this activity is almost completely
lost, indicating that this extension may have evolved to promote premature binding of fMet-
tRNA, thus, ensuring the proper sequence of events during initiation. Mutational analysis
has identified two residues at positions 247 and 248 in the C-terminal extension critical for
the ability of IF3mt to promote the dissociation of fMet-tRNA bound to 28S subunits in the
absence of mRNA. This activity also requires the presence of the linker on the C-terminal
domain [75]. The C-terminal extension is predicted to emerge from the C-terminal
homology domain pointing toward the linker region (Fig. 5B) making it likely that these two
regions of IF3mt work together to dissociate prematurely bound fMet-tRNA.
2.3.5. Binding Site of IF3mt on the Mitochondrial 28S Subunit—Mammalian
mitochondrial ribosomes are protein-rich structures. About half of the proteins in these
particles have homologs in bacterial systems while the other half are unique to
mitochondrial ribosomes. A number of biochemical and biophysical studies have indicated
that the C-terminal domain of E. coli IF3 binds to the platform region of the 30S subunit
while other portions of this factor are located near the cleft and head of the subunit [76-80].
The platform region is one of the more highly conserved regions between bacterial and
mitochondrial ribosomes [16,34]. However, the edges of the platform contain proteins
specific to the mitochondrial ribosome. The head of the 28S subunit lacks a number of the
bacterial ribosomal protein homologs and appears to contain several proteins specific to
mitochondrial ribosomes. To obtain insights into the protein neighbors of IF3mt on the 28S
subunit a chemical cross-linking procedure followed by mass spectrometry was undertaken
[81]
Using this strategy, it was observed that IF3mt cross-links to mammalian mitochondrial
homologs of the bacterial ribosomal proteins S5, S9, S10, and S18(2) (Fig. 6) and to unique
mitochondrial ribosomal proteins MRPS29, MRPS32, MRPS36 and PTCD3 (Pet309). The
cross-link to MRPS29 is somewhat surprising. This protein is also referred to as death
associated protein 3 (DAP3) and is thought to play a role in apoptosis [82,83,84]. Immune
electron microscopy has indicated that MRPS29 is located on the solvent side of the 28S
subunit, on the opposite face of the subunit where IF3mt is thought to bind. However,
MRPS29 is large for a ribosomal protein (nearly 44 kDa) and may have extensions that
penetrate a considerable distance through or around the body of the subunit. PTCD3 is a
pentatricopeptide domain protein known to associate with the small subunit of mitochondrial
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ribosomes [85]. Recent data has shown that PTCD3 is a small subunit ribosomal protein in
mammals (E. Koc, manuscript in preparation). The location of this protein in the
mitochondrial small subunit is not known. However, it cross-links extensively to IF3mt,
suggesting that it may be at least partially located at the interface side of the 28S subunit.
Removal of the N- and C-terminal extensions of IF3mt resulted in the same cross-linking
pattern as the full length IF3mt except that no cross-links were observed to MRPS36. Only
one ribosomal protein (MRPS10 located in the head of the small subunit) was observed
cross-linking to the N-terminal domain. The C-terminal domain (including the linker) cross-
linked to MRPS5, MRPS9, MRPS10 and MRPS18(2) , all of which have bacterial
homologs. Like the full-length factor, the C-terminal domain with the linker cross-linked to
a number of proteins that do not have prokaryotic homologs including MRPS32 and
MRPS36, MRPS29 and PTCD3.
The pattern of cross-links observed between IF3mt and 28S subunits is quite different from
those observed with E. coli IF3 and 30 subunits indicating that contacts between IF3mt and
mitochondrial small subunit are quite different from the contacts between bacterial IF3 and
the small subunit of the prokaryotic ribosome.
3. Polypeptide Chain Elongation in Mammalian Mitochondria
3.1. Overview of the Cycle
The process of polypeptide chain elongation in mammalian mitochondria has many
similarities to the process in prokaryotes [50,86]. This phase of translation has been more
highly conserved during evolution than either the initiation or termination phases. In the
basic sequence of events (Fig. 7), the GTP-bound, active, form of elongation factor Tu (EF-
Tumt) binds aminoacyl-tRNA (aa-tRNA) forming a ternary complex (EF-Tumt• GTP•aa-
tRNA). This ternary complex enters the A-site of the ribosome and is selected if cognate
codon:anticodon interactions can take place (Step 1). Selection of the cognate ternary
complex triggers the hydrolysis of GTP by EF-Tumt and the release of EF-Tu•GDP (Step 2).
Elongation factor Ts (EF-Tsmt) promotes the exchange of GDP for GTP through the
formation of an intermediate EF-Tumt•EF-Tsmt complex (Steps 3 and 4). The ribosome itself
catalyzes peptide bond formation leaving a deacylated tRNA in the P-site and a peptidyl-
tRNA one residue longer in the A-site of the ribosome (Step 5). Mitochondrial elongation
factor G1 (EF-G1mt) then catalyzes the translocation step removing the deacylated tRNA
from the P-site and moving the peptidyl-tRNA from the A-site to the P-site (Steps 6 and 7).
No E-site is shown in this model since analysis of the cryo-EM of the mitochondrial
ribosome suggests that mammalian mitochondrial ribosomes do not possess a site
corresponding to the prokaryotic E-site [34].
All of the elongation factors from mammals have been purified from bovine mitochondria
and the properties of the native factors have been examined [37,87-91]. In addition, the
bovine and human factors have been cloned, expressed in E. coli and further characterized
[92-95]. The properties of the elongation factors have been extensively reviewed previously
[50,96] and the reader should consult those reviews for more detailed information.
3.2: Elongation Factor EF-Tumt
3.2.1.General Properties—Native EF-Tumt has been isolated as a tight complex with
EF-Tsmt from bovine liver. Unlike the prokaryotic system, no free EF-Tumt or free EF-Tsmt
is observed in mitochondrial extracts [91]. The EF-Tumt• EF-Tsmt complex resists
dissociation even at high concentrations of guanine nucleotides. This stability probably
reflects the observation that guanine nucleotide binding to EF-Tumt is over 100-fold weaker
than that observed with E. coli EF-Tu (Kd for GTP = 18 μM and Kd GDP = 1 μM) while
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binding to EF-Tsmt is quite tight (Kd = 5.5 nM) [90,97,98]. The strength of ternary complex
formation depends on the aa-tRNA. For example the Kd for E. coli Phe-tRNA is about 18
nM while the Kd for bovine mitochondrial Phe-tRNA is about 75 nM [99].
3.2.2. The EF-Tumt Gene and Coding Region—The human gene for EF-Tumt
(TUFM) was originally identified as producing a protein overexpressed in certain tumors
[100] and portions of the native protein from Bos taurus were then sequenced from bovine
liver [94]. The chromosomal location of the gene is at 16p11.2 and the gene contains 10
exons. A pseudogene is observed on chromosome 17. EF-Tumt has a mitochondrial import
sequence of 43 amino acids and a mature form that is 409 residues in length with a native
molecular mass of about 45,000 daltons. It is 55-60 % identical to the corresponding factors
from bacteria (Fig. 8A).
The crystal structure of bovine EF-Tumt has been determined [101] and indicates that the
mitochondrial factor is folded into three major domains as is bacterial EF-Tu (Fig. 8 and 9).
Domain I is responsible for binding guanine nucleotides. Domain II, along with domain I,
forms the binding site for the 3′ end of the aa-tRNA and contacts the small subunit of the
ribosome. Domain III interacts with the extended acceptor-TψC helix of the aa-tRNA and
all three domains form a pocket interacting with the 5′ end and a portion of the acceptor
stem of the aa-tRNA (Fig. 8B and C). One of the major differences between the
mitochondrial and bacterial factors is an extension of 11 amino acids at the C-terminus of
EF-Tumt that may be involved in an interaction with the aa-tRNA in the ternary complex
[50,101]. For a detailed discussion of the structure of EF-Tumt, and the binding of guanine
nucleotides to this factor the reader is referred to a previous review [50].
3.2.3. Interaction of EF-Tumt with Mitochondrial aa-tRNA—The structures of
several bacterial ternary complexes have been solved [102,103]. The residues of EF-Tu that
form the binding pocket for the aa-tRNA have been largely conserved between the bacterial
and mitochondrial factors (Fig. 8). However, several residues (Gln290, Arg335 and Pro269)
are not conserved between bacterial EF-Tu and EF-Tumt. The potential importance of these
residues in the ability of EF-Tumt to form a ternary complex with mitochondrial aa-tRNAs
was tested by mutating the residues in the mitochondrial factor to those found in E. coli EF-
Tu [104-106]. Of these residues, Pro269 did not appear to play a critical role; however,
mutation of either Arg335 to Glu or Leu338 to Gln had a strong deleterious effect on the
activity of EF-Tumt. Modeling of the structure of EF-Tumt suggests that Arg335 makes an
important electrostatic contact with the 5′-phosphate of the aa-tRNA. Leu338 is present in a
loop that helps form the binding pocket for the 5′ end of the aa-tRNA and clearly must play
a role in the conformation of that loop to accommodate the formation of the ternary
complex.
Some years ago [107] it was observed that, while EF-Tumt was active when supplied with E.
coli aa-tRNAs, E. coli EF-Tu could not catalyze polypeptide chain elongation with
mitochondrial aa-tRNAs. The bacterial factor was able to form a ternary complex with
mitochondrial aa-tRNA but was unable to deliver them to the A-site of the ribosome.
Domain exchanges between EF-Tumt and E. coli EF-Tu [108] indicated that the ability to
deliver mitochondrial aa-tRNA to the ribosome resides primarily in domains I and II. When
codon:anticodon interactions take place, a signal is sent through the body of the tRNA to
domain I of EF-Tu, triggering GTP hydrolysis. The shorter mitochondrial aa-tRNAs may
not be positioned quite correctly on the ribosome by the bacterial factor and fail to promote
the GTPase activity of EF-Tu effectively. In the absence of GTP hydrolysis, EF-Tu cannot
be used catalytically and, thus, is less active in promoting A-site binding [50].
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3.3: Elongation Factor EF-Tsmt
3.3.1.Sequence Analysis—The gene for human EF-Tsmt (TSFM) maps to chromosomal
location 12q14.1 and spans a bit over 20,000 base pairs. Four isoforms of EF-Tsmt are listed
in RefSeq and NCBI while Expasy lists only two forms (isoforms 1 and 2). The NCBI
isoforms 3 and 4 are extensively truncated at the C-terminus and are unlikely to represent
functional forms. The nomenclature used by NBCI and Expasy for the two likely isoforms
of EF-Tsmt is different leading to some potential confusion. In NCBI, human isoform 1 is
listed as a 346 residue pre-protein containing a small additional exon compared to human
isoform 2 which is 325 amino acids in length including the mitochondrial import sequence.
Expasy defines the shorter 325 residue form (6 exons) as isoform 1 and refers to this as the
‘canonical’ sequence. The 325 residue human form aligns with the form of EF-Tsmt found in
other mammals and is most likely the major active species.
3.3.2. Properties of EF-Tsmt—The most extensively studied form of EF-Tsmt is from
Bos taurus. This protein has been purified from bovine liver as a tight complex with EF-
Tumt. The amino terminus of the mature protein has been determined and this analysis
indicates that there is a 55 residue mitochondrial import signal [93] giving a mature protein
of 283 amino acids with a molecular mass of about 31,000 daltons. EF-Tsmt has been
expressed in E. coli as a His-tagged protein [95]. Under these conditions, it forms a tight
heterologous complex with E. coli EF-Tu that is very difficult to dissociate (Kd is about
10−11). This interaction is almost 100-fold tighter than the homologous E. coli EF-Tu•EF-Ts
complex [95]. Purification of EF-Tsmt requires denaturation of this complex and
renaturation of the remaining free EF-Tsmt.
3.3.3. Structure of the EF-Tu•EF-Tsmt Complex—Bacterial EF-Ts is organized into
four domains: an N-terminal helical domain; a core domain divided into subdomain N and
subdomain C of the core, a dimerization or coiled-coil domain and a C-terminal module
[109]. The low degree of sequence conservation (25-30 %) between bacterial and
mitochondrial EF-Ts made it difficult to align these proteins clearly until direct structural
information became available on the bovine EF-Tumt•EF-Tsmt complex [101] (Figure 9).
This structure indicates that EF-Tsmt has both similarities and differences compared to the
bacterial factors. EF-Tsmt has an N-terminal domain with a similar fold to that of the
prokaryotic factors. However, the core of EF-Tsmt, while forming basically a β-sandwich,
differs in the number and organization of the β-strands. Most striking is the almost complete
erosion of the coiled-coil domain and the C-terminal module found in bacterial EF-Ts.
As indicated in Section 3.1, the major role of EF-Ts is to promote guanine nucleotide
exchange with EF-Tu. Three major areas of contact are observed in the EF-Tumt•EF-Tsmt
complex [101]. The N-terminal domain and subdomain N of the core contact the G-domain
(domain I) of EF-Tumt, while subdomain C of the core contacts domain III of EF-Tumt (Fig.
9). Detailed analysis of the effects of mutations in EF-Tsmt suggests that nucleotide
exchange involves several critical processes [108,110-113]. These include disruption of the
binding site for the Mg2+ ion, which stabilizes the bound guanine nucleotide, a
destabilization of the interactions of the β-phosphate group with EF-Tumt and movements of
portions of EF-Tumt that affect the interactions of the ribose and base with the factor. Thus,
there are extensive changes in the structure of EF-Tumt when it interacts with EF-Tsmt, and
substantial regions of both factors are involved in the nucleotide exchange process. For a
more detailed analysis of the interactions between EF-Tumt and EF-Tsmt the reader is
referred to the structural work and to a previous review [50,101].
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3.4 Mitochondrial Elongation Factor G1
3.4.1. Gene—EF-G is generally viewed as the factor required for the translocation step of
protein biosynthesis. Two forms of EF-Gmt are observed in mitochondrial systems
[114,115]. EF-G1mt is involved in translocation while EF-G2mt appears to be used primarily
during termination (see Section 4.3). The gene for EF-G1mt spans about 50,000 base pairs
and encodes a mRNA of 3,468 nucleotides. It maps to chromosome 3q25. Expasy lists two
isoforms in humans that are splice variants with the larger form (isoform 2) having an
additional 19 amino acids. Isoform 1 (751 amino acids) is viewed as the canonical form and
corresponds to the EF-G1mt generally found in mammals. For an analysis of the sequence of
EF-G1mt, the reader is referred to a previous review [50].
3.4.2. Enzymatic Properties—Native EF-G1mt was purified about 14,000 fold to near
homogeneity from bovine liver mitochondria a number of years ago [88]. The native protein
has an apparent molecular mass of 80,000 daltons on SDS-polyacrylamide gel
electrophoresis. Few detailed enzymatic studies have been carried out on this protein. The
N-terminus is blocked. MitoProtII predicts a 35 amino acid mitochondrial import signal.
Based on this prediction, residues 36-751 were cloned and expressed in E. coli as a His-
tagged protein [92]. EF-G1mt is quite resistant to the antibiotic fusidic acid compared to
other translocases. A number of residues in bacterial EF-G have been implicated in the
sensitivity of this factor to fusidic acid. These residues are generally present in EF-G1mt and
the resistance of this factor to inhibition remains to be understood. The native and the
expressed protein are active with both mitochondrial 55S ribosomes and bacterial 70S
ribosomes. In contrast, E. coli EF-G is not active on mitochondrial ribosomes [88,116]. This
ribosome specificity appears to reside in the L7/L12 stalk of the large ribosomal subunit
[117] that is involved in triggering the GTPase activity of the elongation factors.
4. Polypeptide Chain Termination and Ribosome Recycling in Mitochondria
4.1. Overview of the Process
Several comprehensive reviews covering the termination of translation in mammalian
mitochondria have appeared in the past year and only a brief summary will be provided here
[118-120]. Analysis of mitochondrial genomes indicates that both UAA and UAG serve as
stop codons with the standard UGA stop codon reassigned to tryptophan. In humans two
reading frames terminate with AGA and AGG leading to the initial assignment of these
codons as stop codons. However, no release factor appears to recognize these codons and it
is now believed that they promote a -1 frameshift moving a classical UAG codon into the A-
site for termination [3]. In the current model for termination in mitochondria (Fig. 10), either
the UAA or UGA stop codon appears in the A-site of the ribosome. This codon is
recognized by a release factor mtRF1a (Step 1). Binding of this factor to the ribosome in the
presence of GTP triggers the hydrolysis of the peptidyl-tRNA bond by the peptidyl
transferase center on the 39S subunit and the release of the completed polypeptide (Step 2).
It is not clear how mtRF1a exits the ribosome following polypeptide release. RRF1mt binds
to the A-site of the ribosome along with RRF2mt (also known as EF-G2mt) (Step 3) and
promotes ribosomal subunit dissociation and release of the deacylated tRNA and the mRNA
(Step 4). After RRF1mt and RRF2mt are released from the ribosome (Step 5), another round
of protein synthesis begins. The recycling of the ribosome requires the combined action of
the mitochondrial ribosome recycling factor (RRF1mt ) and EF-G2mt, also referred to as
RRF2mt [115,121,122]. There is no evidence for the presence of a Class II release factor
such as bacterial RF3 in mammalian mitochondria. In bacteria, this factor is normally
required for the removal of RF1 from the ribosome. Consequently, the mechanism by which
mtRF1a is dissociated from mitochondrial ribosomes remains unknown.
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4.2. Mitochondrial Release Factors
Database searching in the late 1990’s led to the identification of an open reading frame
(mtRF1) with 30-40 % homology to bacterial release factors [121]. Subsequent database
searches revealed the presence of three additional open reading frames with homology to
RF1 (mtRF1a, C12orf65 and ICT1), all of which are localized to mitochondria. All of these
factors have the classical GGQ motif that promotes termination by triggering hydrolysis of
the peptidyl-tRNA bond [119]. However, mtRF1 has a variant on the PXT tripeptide motif
expected to function in stop codon recognition while mtRF1a has the expected sequence
[123,124].
Current studies have now demonstrated that mtRF1a functions in termination at UAA and
UAG codons and is, therefore, the release factor used in the decoding process. The roles of
the other factors with homology to class 1 release factors are less clear. Of these ICT1
[125,126] has been shown to function as a ribosome-dependent, codon-independent,
peptidyl-tRNA hydrolase. In this respect, it may play a role in preventing the stalling of
ribosomes on mRNAs that have been cleaved and lack a proper stop codon. When
mitochondrial ribosomes stall at the 3′ end of such a mRNA, ICT1 cleaves the peptidyl-
tRNA releasing the nascent chain and freeing the ribosome for proper recycling [123]. This
system may, thus, play a role equivalent to the transfer-messenger RNA mechanism used in
bacteria [126]. While the role of C12orf65 is not known, it has been suggested that this
protein may play a role in recycling abortive peptidyl-tRNAs that are released from the
ribosome during translational elongation [127].
4.3. Ribosome Recycling in Mammalian Mitochondria
As indicated in Fig. 10, the disassembly of the ribosome •mRNA•tRNA complex requires
the action of the ribosome recycling factor (mtRRF) and EF-G2mt (Steps 3 and 4). Depletion
of mtRRF in human cell lines is lethal, thus indicating that it is an essential protein [128].
Alignment of human mtRRF with the corresponding bacterial factor indicates that the
mitochondrial factor has a long N-terminal extension. This factor is highly conserved in
mammals and readily identified in the genomes of vertebrates. It is generally 30-40 %
identical to the mtRRF of arthropods but less than 30 % identical to the factor in nematodes.
Mammalian mtRRF species share only 25-30 % identity to the bacterial factors, yet mtRRF
can bind to E. coli ribosomes indicating that certain contacts between this factor and the
ribosome have been conserved during evolution [128]. Three variants are listed in NCBI
while seven isoforms are listed in UniProt. These isoforms appear to arise primarily from
alternative splicing; however, there is no experimental evidence that the shorter forms are
expressed. The gene for mtRRF (MRRF) is located on chromosome 9 (9q33.2).
During termination, RRF works in conjunction with the translocase EF-G. As indicated in
Section 4.1, analysis of mammalian genomes indicates the presence of two forms of
mitochondrial EF-G (EF-G1mt and EF-G2mt). EF-G1mt functions as the translocase during
polypeptide chain elongation while EF-G2mt (also referred to as RRF2mt) is thought to act
primarily in chain termination [115]. However, it should be noted that over-expression of
EF-G2mt slightly increases the levels of the respiratory chain complexes in cells carrying
mutations in EF-G1mt suggesting that it may be able to function during elongation to a
limited extent [129]. Many organisms have a single species of EF-G that functions in both
elongation and termination. However, others have two forms as observed in mammalian
mitochondria [130,131]. Some forms of EF-G2 can function in translocation while others
are restricted to the termination phase of translation. EF-G2mt falls largely into this latter
category. In bacterial termination, GTP hydrolysis by EF-G is required for ribosome
recycling. In contrast, GTP hydrolysis by EF-G2mt is not necessary for the ribosomal
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splitting reaction directly. Rather, GTP hydrolysis appears to be required for the release of
EF-G2mt and perhaps of mtRRF as well [115].
The sequence of EF-G2mt is a bit less highly conserved than that of EF-G1mt although
greater than 80 % identity is generally observed with the mammalian species. The
mammalian factor is usually 30-40 % identical to EF-G2mt of the lower eukaryotes. A
number of shorter isoforms of the human factor are listed in UniProt based on various EST
sequences, but there is no experimental evidence that they are functional.
5. Role of the Inner Membrane in the Synthesis of Mitochondrially Encoded
Polypeptides
5.1 Background
There is clear evidence that mitochondrial ribosomes are preferentially associated with the
IM and, in particular, are enriched in the intracristal regions [1]. The association of
mitochondrial ribosomes with the IM allows the synthesis of mitochondrially encoded
proteins near sites of their insertion into the membrane. Little is known about the proteins
promoting the association of mammalian mitochondrial ribosomes with the IM. However, it
is clear that both subunits of the mitochondrial ribosome can be found associated with the
IM [132], and it is very likely that the insertion of these polypeptides into the respiratory
chain complexes is a co-translational process [133-135].
5.2 Yeast Membrane Proteins Interacting with Mitochondrial Ribosomes
A number of proteins have been implicated in the interaction of yeast mitochondrial
ribosomes with the IM (Table 1). The best studied of these is the protein Oxa1p which is
involved in the insertion of a number of proteins including subunit II of cytochrome oxidase
(Cox2) into the IM [134,136-142]. Oxa1p is an integral membrane protein with 5
transmembrane segments (TMS) [142]. It is the mitochondrial homolog of bacterial YidC
which plays a role in both Sec-dependent and Sec-independent pathways in bacteria. The C-
terminal 100 amino acids of Oxa1p are located in the mitochondrial matrix and interact with
mitochondrial ribosomes [143-145]. Evidence from yeast suggests that Oxa1p can be cross-
linked to the nascent chain while it is still on the ribosome and to the ribosomal protein
homologous to L23 which is located at the exit site of the large subunit [140,144].
In addition to Oxa1p, a number of other yeast proteins have been implicated in the insertion
of mitochondrial translation products into the IM and several of these are thought to interact
with the mitochondrial ribosome. However, many of these do not have homologs in
mammalian systems (Table 1), and there appear to be fundamental differences between
yeast and mammals in the mechanism of synthesis and membrane insertion of the
mitochondrial translation products [135,146-150].
In addition to Oxa1, mitochondria contain a homolog of the protein YidC2, (termed Cox18
or Oxa2), found in gram-positive bacteria. Cox18 (Oxa2) which has a homolog in humans,
appears to act post-translationally [145]. The homolog of yeast Mdm38p in humans is
LetM1 (also called LETM1), a 739 amino acid protein with a single TMS which is discussed
in more detail below (Section 5.4).
5.3. Interaction of Mammalian Mitochondrial Ribosomes with Oxa1L
A homolog of Oxa1p (referred to as Oxa1L) is present in humans [151,152]. Human Oxa1L
(like its yeast homolog), is believed to have 5 TMS and a C-terminal tail in the
mitochondrial matrix which interacts with ribosomes. It has recently been reported that
human Oxa1L exists as a 600-700 kDa heterooligomeric complex in mitochondria from
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human embryonic kidney cells [152]. In human cells, knock-down of Oxa1L leads to defects
in the biogenesis of the F1F0-ATP synthase and of Complex I without affecting the levels of
Complexes III or IV. These effects are different from those observed in yeast in which the
assembly of Complex IV is strongly affected by mutations in Oxa1p [138]. The precise
reason for the differences observed is not known. One major possibility is that the human
protein may have evolved to possess specificity for the ATP synthase and Complex I. It is
also possible that another protein may partially compensate for the low Oxa1L levels in the
assembly of Complexes III and IV or that the knockdowns of Oxa1L achieved had not
reached the threshold required to show a defect in the assembly of Complexes III and IV.
The C-terminal region encompassing approximately 100 amino acids of the tail of human
Oxa1L (Oxa1L-CTT) has been cloned and expresses well in E. coli [153]. In contrast to
suggestions made for yeast Oxa1p, the C-terminal tail of human Oxa1L does not form a
coiled-coil helical structure in solution. Rather, this region of Oxa1L exists primarily as a
monomer in solution, although both dimeric and tetrameric forms are observed at high salt
concentrations. A number of techniques have demonstrated Oxa1L-CTT binds to bovine
mitochondrial ribosomes and that this interaction is specific for the large subunit. This latter
observation is expected since Oxa1L is thought to be involved in the insertion of
mitochondrial translation products into the IM and the nascent chain emerges from the exit
tunnel in the large subunit. The binding of Oxa1L-CTT to 39S subunits is an enthalpically
driven process and is governed by a Kd of 0.3 to 0.8 μM. Stoichiometry calculations indicate
that two copies of the C-terminal tail are bound to each 39S subunit [153]. Data derived
from steady-state fluorescence quenching and fluorescence lifetime measurements indicate
that there are extensive contacts between Oxa1L-CTT and the 39S subunit of the ribosome
[154]. These studies also indicate that Oxa1L-CTT undergoes conformational changes and
induced oligomer formation when it binds to the ribosome.
Analysis of proteins from the large subunit that cross-link to Oxa1L-CTT indicate that
mammalian mitochondrial homologs of the bacterial ribosomal proteins L13, L20 and L28
are at or near the binding site of Oxa1L on the ribosome (Fig. 11). In addition, Oxa1L-CTT
can be cross-linked to mammalian mitochondrial specific ribosomal proteins MRPL48,
MRPL49 and MRPL51 suggesting that these proteins are located on the back of the large
subunit in the vicinity of the exit tunnel. No cross-linking of Oxa1L-CTT to proteins
decorating the conventional exit tunnel of the bacterial large ribosomal subunit (L22, L23,
L24 and L29) is observed reflecting fundamental differences in the structures of the bacterial
and mammalian mitochondrial ribosome as discussed in [153].
5.4. LetM1in Humans
In yeast Mdm38p has been implicated in the interaction of ribosomes with the inner
membrane [135]. This protein has a ribosome binding domain located in the mitochondrial
matrix and a region anchored in the membrane itself [155]. Humans appear to have a
homologous protein designated LetM1. This protein has been implicated in Wolf-
Hirschhorn syndrome, a complex syndrome arising from deletions of the short arm of
chromosome 4 [156]. Patients having this syndrome display developmental delays, are
generally mentally retarded and often have epileptic seizures. The severity of the symptoms
is strongly correlated with loss of the LetM1 gene. Depletion of LetM1 does not lead to a
loss of respiratory chain function but does result in mitochondrial swelling and
fragmentation [156]. Since yeast Mdm38p is thought to play a role in the interaction of
mitochondrial ribosomes with the IM, it is possible that human LetM1 could also have this
function. There is a report [157] that human LetM1 interacts with ribosomal protein
MRPL36. This observation is perplexing since the bacterial homolog of this protein (L36) is
a small protein that plays a role in organizing the tertiary structure of the 23S rRNA. It is
located on the interface side of the large subunit and would not be expected to be in contact
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with the membrane. Mdm38p contacts the yeast mitochondrial ribosomal protein that is the
homolog of bacterial L31. Mammalian mitochondrial ribosomes do not have this protein.
Hence, the contacts of LetM1 with the mammalian mitochondrial ribosome, if they occur,
will be different from those observed with the yeast ribosome. It should be pointed out that
recent studies indicate that LetM1 is a Ca2+/H+ antiporter [158,159]. Thus, this protein is
thought to have the dual function of controlling ion flux across the inner membrane and
regulating mitochondrial translation by promoting the interaction of ribosomes with the IM
[155].
6. Mitochondrial Protein Synthesis and Human Disease
6.1 General Comments
Several comprehensive reviews on defects in the human mitochondrial translational system
have recently appeared and only a brief summary will be provided here [96,160-163]. Since
mitochondria generate most of the ATP used by eukaryotic cells, defects in the synthesis of
the respiratory chain components often lead to significant disease states in humans. These
defects can arise either from mutations in the mitochondrial genome itself or from mutations
in nuclear gene products required for the translation of mRNAs encoded in the
mitochondrial genome. For an excellent summary, the reader is referred to Table 1 in Smit et
al. [96].
6.2 Mutations in Mitochondrial tRNAs
Mammalian mitochondrial DNA encodes 22 tRNA species, one for each amino acid and two
for Ser and Leu. This complement of tRNAs is sufficient to decode the genetic code used by
mammalian mitochondria. More than 150 different mutations in the tRNA genes have been
described. The diseases associated with mitochondrial tRNA mutations can lead to defects in
Complexes I, III, IV and the ATP synthase. These defects may arise from a number of
specific issues leading to translational defects, including the failure of the tRNA to be
processed [164], reduced stability of the tRNA [165,166], reduction in aminoacylation
[167-169], reduced ability of the mutated aa-tRNA to interact with EF-Tumt [167,170] or the
failure of the tRNA to be correctly modified [171].
One of the most commonly mutated tRNAs is the tRNALeu responsible for reading the UUR
codons. Mutations here lead to mitochondrial encephalomyopathy with lactic acidosis and
stroke-like episodes (MELAS). The best studied of these mutations is A3243G, which alters
the highly conserved residue A14 in the D-stem of the tRNA leading, among other things, to
structural alterations and a failure of the wobble base in the anticodon to be properly
modified giving rise to translational errors [171]. A second major site for mutations is the
tRNALys gene. For example, the A8344G mutation causes a change in position 55 of the
TψC-loop. This mutation leads to myoclonus epilepsy associated with ragged-red fibers
(MERRF) and arises from defects in aminoacylation and from the lack of taurine
modification in the anticodon loop abolishing proper codon:anticodon interactions.
One of the most thoroughly studied mutations is T4409C in the gene for human
mitochondrial tRNAMet. This mutation has been found to cause dystrophic muscles and
exercise intolerance [172]. At the tRNA level, this mutation leads to the change of the
“universal” U at position 8 to C at the junction of the acceptor arm and the dihydrouridine
arm. This mutation results in a drastic disruption of the structure of the tRNAMet,
significantly reducing its aminoacylation [173]. The small fraction of the tRNAMet that can
be aminoacylated is not formylated by the mitochondrial Met-tRNA transformylase and thus
does not function in initiation. It is also unable to form a stable ternary complex with
elongation factor EF-Tu, which prevents any participation in chain elongation.
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A carefully studied set of mutations in the tRNAPhe gene has also been analyzed [167].
These mutations are associated with a variety of disease states including myopathies,
diabetes, encephalopathies, and deafness. Most of the mutations tested interfere with the
three-dimensional folding of tRNAPhe and lead to defects in aminoacylation and in binding
to EF-Tumt.
6.3 Mutations in Nuclear Genes Required for Mitochondrial Translation
All of the protein factors required for mitochondrial translation are the products of nuclear
genes. Mutations in several of these have been characterized. These include mutations in the
translational elongation and termination factors, ribosomal proteins and ribosome assembly
factors, aa-tRNA synthetases and tRNA and rRNA modifying enzymes [96,162,163].
6.3.1. Mutations in Elongation Factors—Mutations in all three elongation factors have
been identified. A lethal mutation of Arg336 to Gln in EF-Tumt was identified in an infant
with lactic acidosis and fetal encephalopathy [174]. This residue is found in domain II of
EF-Tumt and is in a region that interacts with the acceptor stem of the aa-tRNA in the
ternary complex. This mutation leads to a defect in ternary complex formation with
mitochondrial aa-tRNAs [170,175] resulting in a failure of mitochondrial protein synthesis.
Interestingly, the R336Q mutation has only a mild effect on the interaction of EF-Tumt with
E. coli aa-tRNAs. The difference observed between mitochondrial and bacterial aa-tRNAs
most likely reflects the interaction of this residue with the 5′ phosphate of the aa-tRNA.
This interaction is not important for bacterial aa-tRNAs but appears to be important for the
more structurally fragile mitochondrial tRNAs [102,173].
Mutation of an Arg in EF-Tsmt to Trp (Arg312 in isoform 1, the canonical sequence,
equivalent to Arg333 in isoform 2) is lethal leading to encephalopathy [176]. This mutation
is predicted to disrupt the structure of subdomain C of the core of EF-Tsmt probably
accounting for the reduced levels of EF-Tsmt in patients with this mutation [176]. Arg312
does not make direct contact with EF-Tumt but disruption of the structure of this region of
EF-Tsmt is thought to reduce the interaction of subdomain C with domain III of EF-Tumt.
The mutation reduces the ability of EF-Tsmt to bind EF-Tumt and reduces its nucleotide
exchange activity [170].
Several different mutations have been observed in EF-G1mt [129,174]. For example, the
mutation of Arg250 to Trp in the G’ subdomain of this factor leads to rapidly progressing
mitochondrial encephalopathy. This mutation is expected to affect the ribosomal GTPase
activity of EF-G1mt [177]. Interestingly, mitochondrial protein synthesis was affected in
fibroblasts but not in muscle tissue from this patient reflecting the sometimes unexpected
tissue-specific effects observed with mutations in mitochondrial translation. Unusual tissue-
specific effects have also been observed in other EF-G1mt mutations and are believed to
arise from imbalances in the levels of the elongation factors in the affected tissues [178].
6.3.2. Ribosomal Protein Mutations—Of the approximately 80 identified
mitochondrial ribosomal proteins, mutations are known in only two, MRPS16 and MRPS22
[179,180]. The mutation in MRPS16 is a nonsense mutation (the Arg111 codon to a stop
codon) and leads to agenesis of the corpus callosum, dysmorphism and fatal neonatal lactic
acidosis. MRPS16 is a highly conserved ribosomal protein that has a clear homolog in
bacteria. This mutation has an adverse effect on the assembly of the small ribosomal subunit
leading to decreased levels of the 12S rRNA in the small subunit and a decrease in some but
not all of the other ribosomal proteins of the 28S subunit [181].
A missense mutation in MRPS22 at position 170 changing a conserved Arg residue to His is
lethal in humans. This mutation is associated with edema, fatal cardiomyopathy and
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tubulopathy [180]. MRPS22 has no counterpart in bacteria or yeast and its function is
obscure. This mutation also leads to a defect in the assembly of the 28S subunit. A second
mutation in MRPS22 (Leu 215 to Pro) has also been observed in a patient with Cornelia de
Lange-like dysmorphic features, brain abnormalities and hypertrophic cardiomyopathy
[182].
6.3.3. Mutations in Aminoacyl-tRNA Synthetases and RNA Modifying enzymes
—All of the mitochondrial aminoacyl-tRNA synthetases are encoded by nuclear genes.
Mutations in several of these (Asp, Arg, Ser, Lys and His) are known to lead to disease
states. The reader is referred to Rötig [163] for a recent summary. Recently, two unrelated
children with Leigh syndrome and combined deficiency in oxidative phosphorylation have
been shown to have defects in the mitochondrial Met-tRNA transformylase [183]. This
observation argues strongly that, unlike in yeast, formylation of Met-tRNA is required for
the efficient initiation of translation in humans.
In general, mitochondrial tRNAs contain specific modified bases, and alterations in the
modifying enzymes can produce defects in mitochondrial translation. The best studied
example is mutation in the PUS1 gene that converts uridine in tRNAs to pseudouridine
[184,185]. This minor base is thought to help stabilize the structure of the tRNA. PUS1
modifies both cytoplasmic and mitochondrial tRNAs and, as a result, the effects of
mutations in this gene are somewhat difficult to sort out.
The TRMU gene encodes the mitochondria-specific enzyme that is responsible for the 2-thio
modification of 5-taurinomethyl-2-thio-uridine in the wobble position of certain
mitochondrial tRNAs. TRMU acts as a nuclear modulator of mutations in the 12S rRNA
associated with deafness [186]. It should be pointed out that mutations in the 12S rRNA
(A1555G and C1494T) are important determinants predisposing to deafness.
6.3.4. Other Mutations Affecting Mitochondrial Translation
6.3.4.1. Ribosome Assembly Factors: Little is currently known about the assembly of the
mitochondrial ribosome. However, it is expected that numerous factors will be required for
this process and that mutations in these factors will lead to disease states in humans. Several
candidate genes important for ribosome assembly have been identified. These include two
GTPases (NOA1 and ERAL1) which are likely to be required for the assembly of the small
subunit [187,188]. ERAL1 has recently been shown to bind to the 3′-terminal stem-loop of
the 12S rRNA in the small subunit and binding of ERAL1 to this site appears to promote the
maturation of the 12S rRNA [189]. The proper assembly of the mitochondrial ribosome also
requires methyltransferases possibly for the modification of the rRNA [190,191]. MERTF4,
which has been implicated in mitochondrial transcription, also helps recruit the methylase
NSUN4 to the large ribosomal subunit, an interaction that appears to be required for
ribosome assembly [192].
6.3.4.2. Translational Activators and Other Factors: A number of factors that are
required for the synthesis of at least some of the proteins encoded in the mitochondrial
genome have been identified although currently their roles are poorly understood from a
mechanistic point of view. Mutations in C12orf65 have been observed in patients with Leigh
syndrome, optic atrophy and ophthalmoplegia [127]. The symptoms observed seem to arise
from severe decreases in the levels of Complexes I, IV, and V and a smaller decrease in
Complex III. This protein belongs to the release factor family and contains the GGQ motif
characteristic of the class 1 release factors.
Little is known about the regulation of mitochondrial protein synthesis in mammalian
systems. Yeast contains a number of gene-specific translational activators but, in general,
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these do not have homologs in mammals. A specific defect in the synthesis of Complex IV
subunits has been found in a family with late onset Leigh syndrome [193]. This family has a
mutation in the TACO1 gene. The role of TACO1 is not known, but it may play a role as a
translational activator. A homolog of TACO1 is observed in the genomes of many bacteria,
although the properties and function of this protein in bacteria also remain unknown.
Mutations in the LRPPRC gene have been shown to be the cause of the French Canadian
variant of Leigh syndrome. The LRPPRC protein appears to be a distant relation of yeast
pet309, a translational activator that also stabilizes the mRNAs for COXI and COXIII
[194,195]. The relationship between these proteins appears to reside primarily in PPR motifs
and the question of the function of LRPPRC in humans remains to be determined.
7. Emerging Issues
Much remains to be learned about mammalian mitochondrial protein synthesis. Basic
mechanistic questions remain including how the mRNA is fed into the small ribosomal
subunit at initiation and how the 5′ start codon is positioned in the P-site. While the factors
required for the general processes in initiation, elongation, termination and ribosome
recycling have been identified and a number of detailed studies on these factors have been
carried out, additional factors have been implicated in mitochondrial translation and the
roles of these factors in the translation of all or a subset of mitochondrial mRNAs remain to
be investigated. Mitochondrial translation is certainly regulated and coordinated with other
processes in this organelle including DNA replication and transcription; but the fundamental
interactions involved are still being elucidated.
All of the products of mammalian mitochondrial protein synthesis are components of
macromolecular complexes localized in the inner membrane. There is clear evidence that
mitochondrial ribosomes are preferentially associated with the inner membrane and are
enriched in the intracristal regions. The proteins required for this interaction in mammals are
not well understood. One interesting possibility is that ribosomes synthesizing subunits of
specific complexes are directed to sites where these complexes are being assembled. Such
an interaction would permit the efficient assembly of the respiratory chain complexes and
ATP synthase at specific sites since random insertion into the inner membrane of the
hydrophobic polypeptides synthesized in mitochondria could lead to deleterious interactions.
Understanding this process will require the identification of general and specific proteins
necessary for the interaction of the mitochondrial ribosome with the inner membrane.
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• Mitochondria synthesis critical components of the oxidative phosphorylation
system.
• A biochemical perspective on mitochondrial protein synthesis is provided.
• Mutations in this translational systems leads to human disease.
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Secondary structures of three mitochondrial mRNAs. RNA SHAPE chemistry was used to
analyze the structures of the 5′ ends of the mitochondrial mRNAs and indicated that most
are largely unstructured [26]. The secondary structures of the NADH dehydrogenase
subunits 3 (MTND3) and 5 (MTND5) mRNAs, as well as the cytochrome b (CytB) mRNA
are shown. The free energy values for each stem-loop structure are indicated adjacent to the
stem-loop.
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Model for the initiation phase of mitochondrial translation. In the current model for the
initiation of protein synthesis, mitochondrial initiation factor 3 (IF3mt) actively dissociates
55S ribosomes, forming a transient [IF3mt:55S] complex (Step 1) and leading to the
formation of an IF3mt:28S complex (Step 2). Mitochondrial initiation factor 2 (IF2mt) bound
to GTP binds to the small subunit (Step 3), followed by the fMet-tRNA and mRNA (Step 4),
although the exact order of binding is not clear. The mRNA feeds into the mRNA entrance
gate and the 5′ end pauses at the P-site of the ribosome for inspection of its 5′ start codon.
In the presence of the correct start codon and fMet-tRNA, the mRNA is locked in place by
codon:anticodon interactions to form the 28S initiation complex. If fMet-tRNA binds in the
absence of mRNA, or if the mRNA does not contain a proper start codon, the inspection step
fails. The failed inspection causes the mRNA to continue sliding through the ribosome to
exit. Once the 28S initiation complex has formed, the large subunit joins, and along with the
hydrolysis of GTP to GDP, the initiation factors exit (Step 5) leaving a 55S:fMet-
tRNA:mRNA complex that is ready for the elongation phase of protein synthesis.
Christian and Spremulli Page 36














Organization of initiation factor 2 (IF2). A. Domain alignment of E. coli, G.
stearothermophilus, and M. thermoautotrophicum IF2, as well as mammalian IF2mt. B.
Model for the 3-D structure of IF2mt, based on the cryo-EM map of IF2mt [63]. Domain 3
has been omitted from the structure, since cryo-EM images were not of sufficient resolution
to obtain its coordinates, and no corresponding structures were available in the databases
upon which to build a model. Domain IV is shown in blue, domain V is shown in purple, the
insertion domain is shown in orange, domain VI-C1 is shown in green, and domain VI-C2 is
shown in pink.
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Binding of IF2mt to the E. coli ribosome. This image was taken from the cryo-EM structure
of the 70S:mRNA:fMet-tRNA:IF2mt:GDPNP complex [63] and shows the orientation of
IF2mt on the E. coli ribosome. The bacterial 30S subunit is shown in light yellow and the
bacterial 50S subunit is shown in blue. Defining features of each subunit are labeled,
including the head, shoulder and spur of the small subunit and the central protuberance and
L7/L12 stalk base on the large subunit. IF2mt is shown in red, and the initiator tRNA is
shown in green. The authors thank Dr. Rajendra Agrawal, Wadsworth Center, New York
State Dept. of Health, Albany, NY for the cryo-EM image.
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Organization of IF3mt. A. Domain organization of IF3mt. The regions of IF3mt with
homology to bacterial IF3 are indicated. B. 3-D model of IF3mt based on the crystal
structure of the N-terminal domain of G. stearothermophilus IF3 and the NMR structure of
the C-terminal domain of mouse IF3mt [66]. The N-extension is shown using a dashed grey
line and could not be modeled due to its predicted lack of structure. The N-domain is shown
in yellow, the linker is shown in pink, and the C-domain is shown in blue. The C-extension
is shown using a dashed green line and could not be modeled since no structure could be
predicted for this region of IF3mt.
Christian and Spremulli Page 39














Interaction sites of IF3mt on the small ribosomal subunit. The structure of a “mock”
mitochondrial 28S small subunit was prepared based on the crystal structure of the Thermus
thermophilus 30S ribosomal subunit. The small subunit is shown with the interface side
facing the reader and only homologous proteins and RNA segments present in the
mitochondrial 28S subunit are shown. The ribosomal proteins that can cross-link to IF3mt
are spaced-filled. Small subunit protein S5 is shown in orange, S9 in red, S10 in green, and
S18 in blue.
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Model for the elongation phase of mitochondrial translation. The tRNA containing the
growing polypeptide chain is located in the P-site of the ribosome. EF-Tumt brings the aa-
tRNA to the A-site of the ribosome (Step 1). In concert with the hydrolysis of GTP to GDP,
EF-Tumt leaves the ribosome (Step 2). EF-Tsmt binds to EF-Tumt, displacing the GDP
molecule and forming an EF-Tumt·EF-Tsmt complex (Step 3). A GTP molecule displaces
EF-Tsmt, and an EF-Tumt:GTP complex is formed (Step 4) which can then bind another aa-
tRNA reforming the ternary complex. The large ribosomal subunit catalyzes peptide bond
formation and the growing polypeptide chain is transferred to the tRNA in the A-site of the
ribosome (Step 5). EF-G1mt:GTP binds to the ribosome at the A-site (Step 6) and catalyzes
translocation of the ribosome, moving the deacylated tRNA out of the P-site and the
peptidyl-tRNA from the A-site to the P-site (Step 7). A new cycle of elongation can then
begin.
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Regions of EF-Tumt responsible for interacting with aa-tRNA. A. Alignment of EF-Tumt and
E. coli EF-Tu domain II [106]. The amino acid residues of domain II that interact with the
3′ acceptor stem region of the aminoacyl-tRNA are indicated with a •, and the residues that
interact with the 5′ end of the tRNA are indicated with a B. Interaction of EF-Tu with Cys-
tRNA based on the crystal structure of T. aquaticus EF-Tu:GDPNP:E. coli Cys-tRNACys
(PDB# 1B23). C. Close-up image of the box in B. Image is rotated approximately 90
degrees. The Cys-tRNACys is shown in gray, EF-Tu is shown in orange, and GDPNP is
shown in purple. The residues of EF-Tu that contact the tRNA are shown in pink, the 5′ G
of the tRNA is shown in blue and the A of the 3′ -CCA end of the tRNA is green. The 5′
phosphate group of the tRNA is indicated by the black arrow.
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Crystal structure of the bovine EF-Tumt:EF-Tsmt complex. In the 3-D structure of the bovine
EF-Tumt:EF-Tsmt complex (PDB coordinates 1XB2) [101], EF-Tumt is shown in orange and
EF-Tsmt is in blue. The domains of each protein are labeled and the position of the insertion
present in one isoform of EF-Tsmt is indicated by a red line.
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Model for the termination and ribosome recycling phases of mitochondrial protein synthesis.
As the termination codon (UAG here) enters the A-site of the ribosome, mtRF1a and GTP
bind to the A-site (Step 1) and promote GTP-dependent hydrolysis and release of the
polypeptide chain (Step 2). How mtRF1a is released from the ribosome is not known.
RRF1mt binds to the A-site of the ribosome (Step 3) and is joined by RRF2mt (also termed
EF-G2mt). These factors promote the dissociation of the ribosomal subunits and release of
the deacylated tRNA and the mRNA (Step 4). Following release of RRF1mt and RRF2mt
(Step 5), the ribosome begins another round of protein synthesis.
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Interaction sites of the C-terminal tail of Oxa1L (Oxa1L-CTT) on the large ribosomal
subunit. The 3-D structure of the T. thermophilus 50S ribosomal subunit (PDB 2WRL) is
shown viewed from the solvent side. Regions of the rRNA that are not present in the
mitochondrial 39S subunit have been removed. Mammalian homologs of bacterial ribosomal
proteins predicted to interact with Oxa1L-CTT based on cross-linking studies are shown as
space-filled with L13 (red spheres), L20 (green spheres) and L28 (blue spheres). The
proteins thought to make up the traditional polypeptide exit tunnel (L22, L23, L24, and L29)
are shown in orange spheres and do not cross-link to Oxa1L-CTT. Other large subunit
ribosomal subunits are shown in black.
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Table 1








Co-translational insertion of mitochondrially
synthesized proteins and post-translation insertion of
imported proteins into the IM
Oxa1L [134]
Cox18p
(Oxa2) Post-translational insertion of proteins into IM Cox18 [146]
Mss2 Membrane insertion of specific proteins (Cox2) None [147]
Pnt1p Membrane insertion of specific proteins (Cox2) None [196]
Mba1 Membrane-bound ribosome receptor; None [149]
Mss51p Binds newly synthesized Cox1 None [148]
Coa1p Required for cytochrome oxidase assembly None [197]
Mdm38p Binds ribosomes; Assembly of Complexes III and IV LetM1 [135]
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